US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Wednesday that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved new indications for KEYTRUDA (pembrolizumab) in non-small cell lung carcinoma (NSCLC) and urothelial carcinoma.
KEYTRUDA, in combination with chemotherapy, followed by monotherapy, was approved for NSCLC based on results from the Phase 3 KEYNOTE-671 trial.
For urothelial carcinoma, KEYTRUDA was approved in combination with Padcev (enfortumab vedotin-ejfv) for first-line treatment and as monotherapy for patients ineligible for platinum-containing chemotherapy. These approvals are based on results from the Phase 3 KEYNOTE-A39 and Phase 2 KEYNOTE-052 trials, respectively.
Cumberland Pharmaceuticals partners Qureight for idiopathic pulmonary fibrosis treatment research
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
bioMérieux launches PCR wastewater test to support early detection of infectious disease outbreaks
Clario partners with AWS on advancing clinical data analysis with generative AI
Zynext Ventures invests in Feldan Therapeutics
Sanofi advances respiratory pipeline with positive amlitelimab data and expanded clinical programmes
Sichuan Kelun-Biotech reveals sacituzumab tirumotecan (sac-TMT) clinical studies results
Amgen's IMDELLTRA shows superior overall survival in small cell lung cancer trial